EMEA-000917-PIP02-11 - paediatric investigation plan

bimatoprost

Key facts

• Invented name:
  • Lumigan
  • Lumigan
• Active substance:
  bimatoprost
• Therapeutic area:
  Dermatology
• Decision number:
  P/0089/2012
• PIP number:
  EMEA-000917-PIP02-11
• Pharmaceutical form(s):
  Cutaneous solution
• Condition(s) / indication(s):
  Treatment of androgenic alopecia
• Route(s) of administration:
  Cutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  29/05/2012
• Compliance check done:
  No

Decision

P/0089/2012: EMA decision of 29 May 2012 on the granting of a product specific waiver for bimatoprost (Lumigan), (EMEA-000917-PIP02-11)

Adopted Reference Number: EMA/329833/2012